-
A major breakthrough in Alzheimer's disease! Improve brain cell mitochondrial autophagy to eliminate Alzheimer's symptoms!
Time of Update: 2021-02-16
They found that the process of cleaning brain cells in people and mice with Alzheimer's disease, known as mitochondrial autophagy, was weakened.
When they improved the mitochondrial autophagy of mouse brain cells, the symptoms of Alzheimer's almost disappeared.
-
Genentek's oral SMA therapy has resulted in positive clinical results
Time of Update: 2021-02-16
Following the release yesterday of the latest clinical data from Zolgensma, a gene therapy for SMA, Novarma's results suggest that future SMA patients may have a variety of innovative treatment options.
in a clinical trial called FIREFISH, patients with type 1 SMA were treated with different doses of risdiplam.
-
New drug for lymphoma! TG's new PI3K inhibitor umbralisib has been awarded a breakthrough drug by the FDA
Time of Update: 2021-02-16
Recently, the company announced that the U.S. Food and Drug Administration (FDA) has granted umbralisib (TGR-1202) treatment for breakthrough drug eligibility (BTD) for adult patients with marginal lymphoma (MZL) who have previously received at least one anti-CD20 program.
-
First-line treatment of advanced kidney cancer! Pfizer/Merck Immunity and Targeting Group Bavencio and Inlyta performed strongly
Time of Update: 2021-02-16
. pharmaceutical giant Pfizer and partner Merck KGaA recently jointly announced the evaluation of PD-L1 oncology immunotherapy Bavencio (avelumab) in combination with tyrosine kinase inhibitor Inlyta (avelumab) The interim analysis data for JAVENLIN Renal 101, a key Phase III clinical study for patients with advanced renal cell carcinoma (RCC), was published online in the International Journal of Medicine (NEJM).
-
Fda approves the listing of the ruzurgi (amifampridine) pill
Time of Update: 2021-02-16
ruzurgi was based on a randomized double-blind, placebo-controlled clinical study of 32 adult patients.
The results showed that patients who continued to receive Ruzurgi had less motor capacity than the placebo group.
-
New medicine for rare diseases! Fda approved Ravicti (benzoate glyceride) for urea circulation disorders under 2 months:
Time of Update: 2021-02-16
Recently, the company announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of oral fluids from Gavicti (glycerol phenylbutyrate) to include infants under 2 months of age with urea circulation disorder (UCD).
-
Novarma Asthma Compound Inhaler Phase 2 clinical results were positive
Time of Update: 2021-02-16
May 22, Novartis published data from its Phase 2 clinical study on the treatment of asthma patients with compound therapy IND/GLY/MF (QVM149), both of which showed that QVM149 treatment was better than that of the control group shametero/fluorotikasong (standard therapy) and placebo, significantly improving lung function in asthma patients.
-
Grigg Ingeham and Liu Hanyang bank to develop new drugs for the treatment of NASH and liver disease
Time of Update: 2021-02-16
The two companies will work together to develop innovative double agitations for the treatment of non-alcoholic fatty hepatitis (NASH) and related liver diseases, which bring together GLP-1 and FGF21 activity in a molecule.
-
Noor and Nord's Xultophy showed positive results
Time of Update: 2021-02-16
for patients with type 2 diabetes with inadequate oral treatment control, Novo Nordisk's Xultophy (degludec/liraglutide) significantly delayed the strengthening of treatment time compared to insulin glablin U100.
-
Develop new microbiome immunotherapy! Vedanta C round raised $27 million.
Time of Update: 2021-02-16
Vedanta Biosciences is a clinical biotech company focused on developing a new class of therapies based on well-designed human bacterial complexes for the treatment of immuno-mediated diseases.
-
New drug for type A haemophilia! Bayer's long-acting drug Jivi (BAY94-9027) has been approved by three major markets in the United States, Japan and Europe
Time of Update: 2021-02-16
Kovaltry is an unmodified, full-length recombinant coagulation factor VIII product that is used preventively twice or three times a week in clinical trials to effectively control and prevent bleeding events in patients with type A blood.
-
New drug for hereditary osteopathy! FGF-23 targeted monoantial Crysvita treatment X-chain hypophosphatemia is significantly more effective than conventional:
Time of Update: 2021-02-16
64-week efficacy and safety analysis results: Crysvita relative to conventional therapy after 64 weeks of osteopathic results: (1) cartilage score: by 3 independent blind pediatric radiologists using RGI-C overall score evaluation, Crysvita better than conventional therapy (LS average treatment difference: 1.02, p: The average serum phosphorus levels in the Crysvita treatment group reached the lower limit of the normal range, while the conventional treatment group increased significantly.
-
FDA approves new treatment for resustressable multiple myeloma
Time of Update: 2021-02-16
Recently, the U.S. Food and Drug Administration approved Xpovio (selinexor) tablets in combination with corticosteroid dexamison for the treatment of adult patients with recurring refractic multiple myeloma (RRMM), who have been treated at least four times and whose disease is resistant to several other forms of treatment, including at least two protease inhibitors, immunomodulants, and anti-CD38 monoclonal antibodies.
-
Bronger Ingeham announces that THESCIS ® clinical trials have reached their primary endpoint
Time of Update: 2021-02-16
recently, Grigg Ingham announced that the SENSCIS® clinical trial has reached its primary endpoint: reducing the annual rate of decline in forced lung capacity (FVC) in patients with systemic sclerosis-related interstitiotic pulmonary disease (SSc-ILD).
-
Gilead plans to apply for approval for the new rheumatoid arthritis drug Filgotinib
Time of Update: 2021-02-16
's brief announcement this morning comes three months after Gilead and its development partner Galapagos NV announced that its Phase III FINCH 3 trial reached the primary endpoint of the American Rheumatology Society's 20% Response (ACR20) patient remission rate at 24 weeks.
-
Fda approves Benlysta intravenous infusions for children with systemic lupus erythematosus
Time of Update: 2021-02-16
clinical trial looked at the efficacy of belimumab, which evaluated the efficacy, safety and pharmacodynamics of 93 active SLE children aged 5-17 years with standard therapy and placebo plus standard therapy.
The drug's safety and pharmacodynamic characteristics in child patients are consistent with among adult SLE patients.
-
FDA approves first nasal psychic drug for chronic rhinitis-sinusitis
Time of Update: 2021-02-16
The effectiveness and safety of Dupixent was determined in two studies, 724 of which were patients aged 18 and older with chronic nasal-sinusitis accompanied by nasal polyp, and who had symptoms despite taking endotholsteroids.
-
Prevention of respiratory package virus (RSV)! FDA grants AstraZeneta a breakthrough drug for next-generation antibody MEDI8897:
Time of Update: 2021-02-16
British pharmaceutical giant AstraZeneca recently announced that the U.S. Food and Drug Administration (FDA) has awarded MEDI8897 Breakthrough Treatment Designation (BTD), a half-life-extending respiratory syncytial virus (RSV) fusion (F) protein monoclonal antibody (Mab) that is being developed to prevent lower respiratory infection (LRTI) caused by RSV.
-
The FDA granted Bringer Ingeham and Lilly's Jardiance fast-track eligibility
Time of Update: 2021-02-16
"We look forward to working closely with the FDA as we explore the potential of Jardiance to improve prognosis in patients with chronic heart failure." Related: Thank you, Jardiance: Diabetes drug sales ease Bronger Ingeham's patent losses In a landmark 2015 Empa-Reg study, people with type 2 diabetes had a 14 percent lower risk of major cardiovascular events and established a new frontier in diabetes drugs, with Jardiance emerging in the SGLT2 category.
-
Soryuan Bio has been granted a new drug to treat Alzheimer's disease
Time of Update: 2021-02-16
recently, precision medicine company Soyuan Bio announced that it has obtained authorization from Finland's Orion Corporation to treat ORM-12741, a new drug for Alzheimer's disease.
, more than 540 patients in 11 clinical studies have taken ORM-12741, confirming the drug's safety and tolerance.
![9-[1,1'-biphenyl]-4-yl-3,3'-Bi-9H-carbazole](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
